Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis, where early metastatic dissemination and rich desmoplastic stroma limit the therapeutic efficacy. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor that is involv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kristina Živić, Marijana Pavlović, Marija Ostojić, Danijel Galun, Aleksandar Pavić, Tatjana Srdić-Rajić, Jelena Grahovac
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-06-01
Edice:	Cells
Témata:	pancreatic cancer nischarin rilmenidine drug repurposing metastasis
On-line přístup:	https://www.mdpi.com/2073-4409/15/11/1032
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!